Eloxx Pharma Analyst Price Targets - Benzinga

Eloxx Pharmaceuticals Inc

ELOXNASDAQ

Trade with Public

Trade with Public

$12.40

-0.34-2.67%

Últ. Act.: Nov 5, 11:33 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Eloxx Pharma Analyst Price Targets - Benzinga

Eloxx Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eloxx Pharma (ELOX).

Price Target Range — 2 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingOutperform# Analysts5Avg. Consensus PT$38Upside to Avg. PT+202.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$43→$40
Oct 15, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	—
Sep 18, 2026	Leerink Partners	Joseph Schwartz	Initiate	Outperform	$32
Aug 24, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$43
Aug 20, 2026	LUCID CAPITAL MARKETS	Dev Prasad	Initiate	Buy	$38
Jul 22, 2026	LifeSci Capital	Rami Katkhuda	Initiate	Outperform	$40
Jul 20, 2026	Guggenheim	Vamil Divan	Initiate	Buy	$43

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40

Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.

Benzinga Newsdesk

This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32

Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Eloxx Pharma, Maintains $43 Price Target

Guggenheim analyst Vamil Divan reiterates Eloxx Pharma (NASDAQ:ELOX) with a Buy and maintains $43 price target.

Benzinga Newsdesk

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.

Benzinga Newsdesk